Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 25, 2001

View Archived Issues

Phase II trial initiated for BLP25 vaccine for prostate cancer

Trinity Biotech launches new one-step malaria test

Replagal therapy for Fabry's disease approved in New Zealand and Iceland

Phase I/II trial results for CG-7870 discussed at ECCO 11

Micafungin undergoing regulatory review in Japan

Antiemetic agent developed in Japan to be submitted for approval within the year

Clinical testing of NIK-333 commences

Compound for SIADH designated an orphan drug in Japan

Vasopeptidase inhibitors from Bioprojet to be developed, marketed by Lilly

U.S. clinical trials of new polyamine drug SL-11047 will now begin

Induction of therapeutic angiogenesis by molgramostim in patients with CAD

Demegen expands pipeline for treatment of cystic fibrosis through CFF grant

Zindaclin receives approval in U.K. as acne treatment

ALT-711 enters a second systolic hypertension trial

Minimal toxicity seen in phase I studies of new camptothecin conjugate

Novo Nordisk makes further investment in Aradigm's AERx iDMS program

Combination therapy with PKC-412, 5-FU and leucovorin evaluated in phase I trial

Cell Therapeutics and Chugai establish agreement to develop cancer product

Biomira to commence interim analysis of Theratope vaccine in the third quarter of 2002

Geron grants Dendreon nonexclusive license for telomerase technology

Genzyme receives FDA complete response letter for Fabrazyme

Nonopioid analgesic effects reported for nitecapone and other COMT inhibitors

New substituted thiazole derivatives synthesized at Janssen and use of the same

Patent coverage obtained for new myt1 kinase inhibitors

Series of selective COX-2 inhibitors useful for wide range of disorders according to recent patent

Bayer presents new compounds stimulating erythropoiesis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...